These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33095875)

  • 41. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
    Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
    JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
    Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
    Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
    Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
    JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.
    McCaffrey S; Black RA; Nagao M; Sepassi M; Sharma G; Thornton S; Kim YH; Braverman J
    J Med Internet Res; 2019 Jan; 21(1):e11302. PubMed ID: 30617041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.
    Stuver R; Geller S
    Front Immunol; 2023; 14():1284045. PubMed ID: 37868986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
    Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
    Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
    Maitrepierre F; Schissler C; Cribier B; Lipsker D
    Ann Dermatol Venereol; 2020 Mar; 147(3):198-201. PubMed ID: 31959414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell signaling in cutaneous T-cell lymphoma microenvironment: promising targets for molecular-specific treatment.
    Rendón-Serna N; Correa-Londoño LA; Velásquez-Lopera MM; Bermudez-Muñoz M
    Int J Dermatol; 2021 Dec; 60(12):1462-1480. PubMed ID: 33835479
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.
    Sonego B; Ibatici A; Rivoli G; Angelucci E; Sola S; Massone C
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
    Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
    J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
    Trager MH; Geskin LJ
    G Ital Dermatol Venereol; 2019 Dec; 154(6):681-695. PubMed ID: 31859467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
    Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
    J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma.
    Afifi S; Mohamed S; Zhao J; Foss F
    Expert Opin Drug Saf; 2019 Sep; 18(9):769-776. PubMed ID: 31303060
    [No Abstract]   [Full Text] [Related]  

  • 56. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.
    Porcu P; Hudgens S; Horwitz S; Quaglino P; Cowan R; Geskin L; Beylot-Barry M; Floden L; Bagot M; Tsianakas A; Moskowitz A; Huen A; Dreno B; Dalle S; Caballero D; Leoni M; Dale S; Herr F; Duvic M
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):97-105. PubMed ID: 33158772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma.
    Kleinhans M; Tun-Kyi A; Gilliet M; Kadin ME; Dummer R; Burg G; Nestle FO
    Blood; 2003 Feb; 101(4):1487-93. PubMed ID: 12393570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Value of Immunohistochemical Expression of TOX, ICOS, and GATA-3 in the Diagnosis of Mycosis Fungoides.
    Atwa HA; Abdelrahman DI
    Appl Immunohistochem Mol Morphol; 2023 Mar; 31(3):163-171. PubMed ID: 36805367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications.
    Luna DE; Shinohara MM
    Curr Hematol Malig Rep; 2023 Jun; 18(3):83-88. PubMed ID: 37017872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.